Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Luis D Borrero-GarcíaMaria Del Mar MaldonadoJulia Medina-VelázquezAngel L Troche-TorresLuis VelazquezNilmary Grafals-RuizSuranganie DharmawardhanePublished in: BMC cancer (2021)
Rac inhibition may represent a viable strategy for treatment of EGFR/HER2 targeted therapy resistant breast cancer.